Regulus Therapeutics names new vice president, DMPK
3 June 2022 -

Regulus Therapeutics Inc. (Nasdaq: RGLS), a US-based biopharmaceutical company, announced on Thursday that it has named Amin Kamel, PhD, as its new vice president, DMPK.

In the new role, Dr Kamel will support clinical development, in particular advancement of the firm's lead candidate, RGLS8429, which is being produced for patients with autosomal dominant polycystic kidney disease (ADPKD).

Dr Kamel has served as the scientific director of Takeda, Drug Metabolism and Pharmacokinetics. He held the position of principal investigator at Biogen, research investigator for Novartis Institutes for BioMedical Research and worked for a number of years as a research scientist at Pfizer Global Research and Development.